NCT06707181View on ClinicalTrials.gov

Comparative Study for Medical Therapy for Lower Ureteral Stones

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

May 20, 2024

Study Completion Date

August 18, 2024

Conditions
Lower Ureteral Stones
Interventions
DRUG

• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf

• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.

Trial Locations (1)

Unknown

Faculty of Medicine, Fayoum University, Al Fayyum

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT06707181 - Comparative Study for Medical Therapy for Lower Ureteral Stones | Biotech Hunter | Biotech Hunter